Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

prnewswire

Oct 18, 2025

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱^®) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.

Continue Reading

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576048378"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576048378\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576048378?lang=en_US&edition=fundamental","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","is_english":false,"pubTime":"2025-10-18 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576048378","market":"sg","top_or_hot":-1,"title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","media":"prnewswire","content":"<html><body><div>\n<div>\n<p> <span>CHENGDU, China</span>, <span>Oct. 18, 2025</span> /PRNewswire/ -- <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱<sup>®</sup>) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.</p>\n<div>\n<span>\nContinue Reading\n                  <br/>\n<i></i>\n</span>\n</div>\n<div>\n<div>\n<div>\n<div>\n</div>\n<div>\n<div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1055060725\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">prnewswire </p>\n<p class=\"h-time\">2025-10-18 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<p> <span>CHENGDU, China</span>, <span>Oct. 18, 2025</span> /PRNewswire/ -- <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱<sup>®</sup>) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.</p>\n<div>\n<span>\nContinue Reading\n                  <br/>\n<i></i>\n</span>\n</div>\n<div>\n<div>\n<div>\n<div>\n</div>\n<div>\n<div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地产信托","start_time":0,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","article_id":"2576048378","we_media_id":"1055060725","thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","pubTimestamp":1760798760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"prnewswire","introduction":"prnewswire","home_visible":1,"id":"1055060725","head_image":"https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c"},"summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4231":"零售房地产信托","ADC":"艾格里房产","BK4225":"医疗保健房地产信托","BK4190":"消闲用品","HR":"医疗保健房地产信托","BC":"宾士域","BK7095":"多种金属与采矿","ADC.AU":"ACDC Metals Ltd","BK4080":"零售业房地产投资信托","BK4203":"医疗保健房地产投资信托"},"translate_title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2-Breast Cancer at 2025 ESMO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"BC":1,"HR":1.5,"ADC.AU":1},"content_text":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.\n\n\nContinue Reading\n                  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}